癌癥

Zon 課題組用斑馬魚(yú)胚胎進(jìn)行藥物篩選, 發(fā)現(xiàn)了雙氫乳清酸酯脫氫酶 (Dihydroorotate dehydrogenase, DHODH)的抑制劑, 比如來(lái)氟米特(Leflunomide), 能抑制神經(jīng)脊細(xì)胞發(fā)育。在哺乳動(dòng)物模型里的實(shí)驗(yàn)表明, 通過(guò)抑制DHODH 可以有效抑制黑素瘤在體外和體內(nèi)的增殖。Leflunomide 也被批準(zhǔn)進(jìn)入了臨床實(shí)驗(yàn), 與Vemurafenib 聯(lián)合用藥治療黑素瘤(ClinicalTrials.gov Identifier NCT01611675)。

（Patton, E.E., Widlund, H.R., Kutok, J.L., Kopani, K.R., Amatruda, J.F., Murphey, R.D., Berghmans, S., Mayhall, E.A., Traver, D., Fletcher, C.D., et al. (2005). BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Current biology : CB 15, 249-254